Detection at diagnosis of tumor cells in bone marrow aspirates of patients with small-cell lung cancer (SCLC) and clinical correlations
| Autor: | Felice Pasini, A. Masotti, Giuseppe Pelosi, R. Mostacci, E. Recaldin, P. Spagnolli, Antonio Santo, Gianluigi Cetto |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Antigens
Differentiation T-Lymphocyte Pathology medicine.medical_specialty Lung Neoplasms Cell Adhesion Molecules Neuronal Immunocytochemistry Enolase Antigen Antigens CD Bone Marrow medicine Biomarkers Tumor Humans Stage (cooking) Carcinoma Small Cell Bone Marrow Diseases Performance status business.industry Respiratory disease Hematology medicine.disease Prognosis CD56 Antigen Survival Rate medicine.anatomical_structure Oncology Immunohistochemistry Bone marrow business |
| Zdroj: | Annals of oncology : official journal of the European Society for Medical Oncology. 6(1) |
| ISSN: | 0923-7534 |
| Popis: | Summary Background Immunocytochemistry has often been used to identify tumor cells in bone marrow aspirate (BMA) of SCLC patients in order to improve the results of conventional histomorphology. However, whether the detection of bone marrow microlocalisation at diagnosis had implications for prognosis has not been clear. Patients and methods Eighty-four slides (44 patients) and 66 bone marrow biopsies (from 42/44 patients) were evaluated. Cytospins of BMA were incubated wih the monoclonal antibody (MAb) NCC-LU-243, recognising the cluster 1 antigen (NCAM) and then stained by the APAAP (alkaline phosphatase-anti-alkaline phosphatase) method. The relationship among BMA and PS (performance status), NSE (neuron-specific enolase), stage, survival was also studied. Results 33/84 (39%) BMA were positive for NCAM, compared with 8/66 (12%) bone marrow biopsies (p ─ 0.009), (17/44 and 6/42 patients, respectively). Moreover, BMA was positive for NCAM in 6/19 patients with limited disease. The presence of positive BMA did not correlate with PS, NSE or stage, but patients with positive BMA had shorter survivals than those with negative BMA (median survival: 7 and 12 months, respectively, p ─ 0.007). Conclusions Bone marrow involvement detected by immunocytochemistry appears to be related to survival but not to parameters of tumor burden (NSE, stage), suggesting that this technique might help to select patients with better prognoses for new therapeutic strategies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|